SCHEMBL20510702

SCHEMBL20510702

O=C(O)CCCCC(=O)ON1CCCC1=O

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.40
CYP1A2 P05177 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GAA P10253 2/20 0.36
TSHR P16473 3/20 0.35
NFKB1 P19838 1/20 0.34
PMP22 Q01453 1/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
PTGS1 P23219 4/20 0.33
PTGS2 P35354 4/20 0.33
CASP1 P29466 1/20 0.33
PTGER3 P43115 1/20 0.32
PTGER2 P43116 1/20 0.32
ALDH1A1 P00352 1/20 0.32
F13A1 P00488 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21201581 0.98 LMNA (0.39) LMNACYP1A2MAPK1SMN1; SMN2GAA
SCHEMBL8481372 0.92 LMNA (0.43) LMNASMN1; SMN2GAATSHRKMT2A
SCHEMBL8536341 0.87 GAA (0.40) LMNACYP1A2MAPK1SMN1; SMN2GAA
SCHEMBL23813764 0.86 LMNA (0.39) LMNACYP1A2MAPK1SMN1; SMN2GAA
SCHEMBL26079396 0.84 GAA (0.50) LMNASMN1; SMN2GAAKMT2A
SCHEMBL9387072 0.84 GAA (0.50) LMNASMN1; SMN2GAAKMT2A
SCHEMBL27362262 0.84 LMNA (0.38) LMNACYP1A2SMN1; SMN2GAATSHR
SCHEMBL27547194 0.83 GAA (0.49) LMNASMN1; SMN2GAAKMT2A
SCHEMBL24722323 0.83 LMNA (0.37) LMNASMN1; SMN2GAATSHRKMT2A
SCHEMBL1982542 0.83 GAA (0.49) LMNASMN1; SMN2GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11041009-B2 Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes MERCK SHARP & DOHME CORP. (US) 2021-06-22 US disclosed
US-20200087375-A1 GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME CORP. (US) 2020-03-19 US disclosed
EP-3600381-A1 GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES Merck Sharp & Dohme Corp. (US) 2020-02-05 EP disclosed
WO-2018175272-A1 GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME CORP. (US) 2018-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200087375-A1 GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES GPR119, IAPP, INSR LMNA 4430/4885CYP1A2 3484/4885MAPK1 2541/4885
US-11041009-B2 Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes GPR119, IAPP, INSR LMNA 4430/4885CYP1A2 3484/4885MAPK1 2541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.